Blood‐based biomarkers for Alzheimer's disease
A Leuzy, N Mattsson‐Carlgren, S Palmqvist… - EMBO molecular …, 2022 - embopress.org
Neurodegenerative disorders such as Alzheimer's disease (AD) represent a mounting public
health challenge. As these diseases are difficult to diagnose clinically, biomarkers of …
health challenge. As these diseases are difficult to diagnose clinically, biomarkers of …
Biomarkers for Alzheimer's disease: current status and prospects for the future
K Blennow, H Zetterberg - Journal of internal medicine, 2018 - Wiley Online Library
Accumulating data from the clinical research support that the core Alzheimer's disease (AD)
cerebrospinal fluid (CSF) biomarkers amyloid‐β (Aβ42), total tau (T‐tau), and …
cerebrospinal fluid (CSF) biomarkers amyloid‐β (Aβ42), total tau (T‐tau), and …
Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration
With the potential development of new disease-modifying Alzheimer's disease (AD)
therapies, simple, widely available screening tests are needed to identify which individuals …
therapies, simple, widely available screening tests are needed to identify which individuals …
A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease
Abstract Development of tau-based therapies for Alzheimer's disease requires an
understanding of the timing of disease-related changes in tau. We quantified the …
understanding of the timing of disease-related changes in tau. We quantified the …
Prospective longitudinal atrophy in Alzheimer's disease correlates with the intensity and topography of baseline tau-PET
β-Amyloid plaques and tau-containing neurofibrillary tangles are the two neuropathological
hallmarks of Alzheimer's disease (AD) and are thought to play crucial roles in a …
hallmarks of Alzheimer's disease (AD) and are thought to play crucial roles in a …
Tau PET imaging in neurodegenerative tauopathies—still a challenge
The accumulation of pathological misfolded tau is a feature common to a collective of
neurodegenerative disorders known as tauopathies, of which Alzheimer's disease (AD) is …
neurodegenerative disorders known as tauopathies, of which Alzheimer's disease (AD) is …
Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer's disease
N Mattsson-Carlgren, E Andersson, S Janelidze… - Science …, 2020 - science.org
The links between β-amyloid (Aβ) and tau in Alzheimer's disease are unclear. Cognitively
unimpaired persons with signs of Aβ pathology had increased cerebrospinal fluid (CSF) …
unimpaired persons with signs of Aβ pathology had increased cerebrospinal fluid (CSF) …
Discriminative accuracy of [18F] flortaucipir positron emission tomography for Alzheimer disease vs other neurodegenerative disorders
Importance The positron emission tomography (PET) tracer [18 F] flortaucipir allows in vivo
quantification of paired helical filament tau, a core neuropathological feature of Alzheimer …
quantification of paired helical filament tau, a core neuropathological feature of Alzheimer …
Prevalence and family-related factors associated with suicidal ideation, suicide attempts, and self-injury in children aged 9 to 10 years
DC DeVille, D Whalen, FJ Breslin, AS Morris… - JAMA network …, 2020 - jamanetwork.com
Importance Although suicide is a leading cause of death for children in the United States,
and the rate of suicide in childhood has steadily increased, little is known about suicidal …
and the rate of suicide in childhood has steadily increased, little is known about suicidal …
The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers
NJ Ashton, A Leuzy, TK Karikari… - European journal of …, 2021 - Springer
Purpose The development of blood biomarkers that reflect Alzheimer's disease (AD)
pathophysiology (phosphorylated tau and amyloid-β) has offered potential as scalable tests …
pathophysiology (phosphorylated tau and amyloid-β) has offered potential as scalable tests …